Research programme: siRNA hearing loss therapies - Alnylam Pharmaceuticals
Latest Information Update: 16 May 2014
At a glance
- Originator Sirna Therapeutics
- Developer Massachusetts General Hospital
- Mechanism of Action RNA inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Sensorineural hearing loss